Buying battle-tested dividend aristocrats can be a winning strategy for those seeking durable retirement income. What's even better is if they also carry strong balance sheets and are attractively valued. In this article, I highlight 2 such picks, which, on a combined basis, offer immediate diversification and potential for market-beating total returns.
Medtronic expects its fiscal 2025 third-quarter revenues to reflect an unfavorable impact of 1% from currency translation.
In the closing of the recent trading day, Medtronic (MDT) stood at $91.69, denoting a +0.79% change from the preceding trading day.
In the most recent trading session, Medtronic (MDT) closed at $91.99, indicating a +0.63% shift from the previous trading day.
Shares of Medtronic (MDT 0.32%) are off to a fantastic start in 2025, already rising by 13% year to date. The medical devices giant had some weakness in recent years amid disappointing trends from its diabetes segment, but it appears to have finally turned the corner with its increasingly diversified operating profile.
When you're buying income stocks, a company's underlying business is arguably still the most crucial factor to consider, even more than the dividend yield. Corporations with high yields may look attractive, but sometimes these are unsustainable.
If you're a dividend investor, I can understand why -- because dividend-paying stocks offer a triple upside: As long as the underlying company is healthy and growing, its stock price will likely increase over time. It will deliver value to shareholders via a cash distribution, as well, in the form of dividends.
Medtronic (MDT) closed at $90.19 in the latest trading session, marking a +1.05% move from the prior day.
Medtronic said on Monday it will appoint Renault's finance chief Thierry Piéton as its Chief Financial Officer, effective March 3.
Medtronic (MDT) concluded the recent trading session at $85.40, signifying a +0.18% move from its prior day's close.
Medtronic plc (NYSE:MDT ) 43rd Annual J.P. Morgan Healthcare Conference Call January 13, 2025 5:15 PM ET Company Participants Geoff Martha - Chief Executive Officer Sean Salmon - EVP & President, Cardiovascular Portfolio Gary Corona - Interim Chief Financial Officer Que Dallara - EVP & President, Diabetes Operating Unit Conference Call Participants Robbie Marcus - JPMorgan Robbie Marcus Good afternoon, everyone.
At the intersection of healthcare and technology, medtech companies are leveraging innovative solutions to improve patient care and health outcomes. Industry leaders are well-positioned to deliver shareholder value by addressing the growing healthcare demands of an aging global population and the rising prevalence of chronic diseases.